Brenntag Q1 Report 2023

Brenntag continued to manage challenging macroeconomic conditions well in Q1 2023.

Better performance in Q1 2023 compared to Q4 2022 visible in top and bottom line.

Gradual Volume improvements on the group level and slightly positive momentum towards the end of Q1.

Sales -1% vs PY. Operating Gross Profit -0,3% vs PY.

The Pharma business performed very well. However, this was not enough to fully offset the subdued demand in other focus industries, where customers ran down inventories that had been built up previously and waited for prices to fall in light of initial signs of prices stabilizing.

Inflationary pressure expected to persist